This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2014 Aug 5;64(5):528-9.

doi: 10.1016/j.jacc.2014.03.053.

Effect of spironolactone in CV mortality in hemodialysis patients

Arun Kannan, Chithra Poongkunran, Saravanan Balamuthusamy

PMID: 25082591
DOI: 10.1016/j.jacc.2014.03.053

Free article

Comment

Effect of spironolactone in CV mortality in hemodialysis patients

Arun Kannan et al. J Am Coll Cardiol. 2014.

Free article

. 2014 Aug 5;64(5):528-9.

doi: 10.1016/j.jacc.2014.03.053.

Authors

Arun Kannan, Chithra Poongkunran, Saravanan Balamuthusamy

PMID: 25082591
DOI: 10.1016/j.jacc.2014.03.053

No abstract available

PubMed Disclaimer

Comment on

Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients.
Matsumoto Y, Mori Y, Kageyama S, Arihara K, Sugiyama T, Ohmura H, Yakushigawa T, Sugiyama H, Shimada Y, Nojima Y, Shio N. Matsumoto Y, et al. J Am Coll Cardiol. 2014 Feb 18;63(6):528-36. doi: 10.1016/j.jacc.2013.09.056. Epub 2013 Oct 30. J Am Coll Cardiol. 2014. PMID: 24184249 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information